论文部分内容阅读
有史以来规模最大的晚期食管癌(食管和胃)第Ⅲ阶段研究 REAL2的结果显示,Xeloda(希罗达)可代替5-氟尿嘧啶(5-FU)、oxaliplatin(奥沙利铂)可代替 cisplatin(顺铂)用于一线治疗晚期食管癌患者。在英国和欧洲的大部分地区,该病症的标准疗法是表阿霉素(epirubicin)、顺铂和5-氟尿嘧啶的综合治疗(又称 ECF)。此外,试验显示与接受标准的 ECF 化疗的患者相比,利用希罗达、奥沙利铂和表阿霉素的综合疗法(称为 EOX)治疗的患者的生命可得以大大延长。在整个治疗期内,患者需通过连接在其手臂上的输液以助于每天不间断地注射 ECF;而口服希罗
REAL2, the third-stage study of the largest advanced esophageal cancer (esophagus and stomach) in history, showed that Xeloda could replace 5-fluorouracil (5-FU) and oxaliplatin instead of cisplatin Cisplatin) for first-line treatment of advanced esophageal cancer patients. In most parts of the UK and Europe, the standard regimen for this condition is the combination of epirubicin, cisplatin and 5-fluorouracil (also known as ECF). In addition, trials have shown that patients treated with combination therapy of Xeloda, oxaliplatin and epirubicin (referred to as EOX) can be significantly prolonged in life compared to patients receiving standard ECF chemotherapy. Throughout the treatment period, patients need to be connected to their arms through the infusion to facilitate non-stop daily injection of ECF; and oral Hiro